More revolutionary news on the health-care front: Eatontown, New Jersey-based American CryoStem Corporation (OTC:CRYO) saw its stock shoot through the roof Wednesday, on word of its application to the U.S. Food and Drug Administration (FDA).
The company, a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, announced today that it has submitted its first Investigational New Drug Application for its ATCell™ product to the FDA.
The federal body’s acceptance for review of CryoStem’s IND application is a “significant milestone” for the company and represents a meaningful step forward in the treatment of patients suffering from Post Concussion Syndrome. It also aids in the advancement of Regenerative Medicine.
CRYO’s Phase I Clinical Trial, upon FDA approval, will investigate ATCell™ to provide assessments of the safety and tolerability, and to collect clinical data regarding the alleviation of symptoms associated with Post-Concussion Syndrome.
Stock prices were healthy, though, climbing five cents, or 11.6%, to 48 cents, on volume of 46,000
